Tag Archives: Cidara Therapeutics

Cidara Therapeutics (CDTX) Receives a Buy from Needham

In a report released today, Alan Carr from Needham maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $3.15. According to TipRanks.com, Carr is a

Oppenheimer Remains a Buy on Cidara Therapeutics (CDTX)

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) today and set a price target of $6.00. The company’s shares closed last Monday at $3.15. According to TipRanks.com, DeGeeter is a 4-star analyst with

Cidara Therapeutics (CDTX) Receives a Buy from Oppenheimer

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) today and set a price target of $6.00. The company’s shares closed last Monday at $3.16. According to TipRanks.com, DeGeeter is a 4-star analyst with

The President & CEO of Cidara Therapeutics is Exercising Options

Yesterday it was reported that the President & CEO of Cidara Therapeutics (CDTX – Research Report), Jeffrey Stein, exercised options to buy 32,283 CDTX shares at $2.51 a share, for a total transaction value of $81.03K. The options were close

Cantor Fitzgerald Keeps Their Buy Rating on Cidara Therapeutics (CDTX)

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) today and set a price target of $15. The company’s shares opened today at $2.84. Chen noted: “CDTX’s pipeline is focused on better ways

The COO of Cidara Therapeutics (NASDAQ: CDTX) is Selling Shares

Yesterday, the COO of Cidara Therapeutics (CDTX – Research Report), Paul Daruwala, sold shares of CDTX for $5,712. In addition to Paul Daruwala, one other CDTX executive reported Sell trades in the last month. See today’s analyst top recommended stocks